Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Goldsby
Robert
R
Pulsipher
Mike
M
Adams
Roberta
R
Coffin
Cheryl
C
Albritton
Karen
K
Wagner
Lars
L
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D016026:Bone Marrow Transplantation; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D003131:Combined Modality Therapy; D004487:Edema / Q000209:etiology; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D000077146:Irinotecan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy; D017254:Leukemic Infiltration / Q000188:drug therapy; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008297:Male; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D018242:Neuroectodermal Tumors, Primitive / Q000556:secondary / Q000628:therapy; D010879:Piperazines / Q000009:adverse effects*; D010996:Pleural Effusion / Q000139:chemically induced*; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects; D011743:Pyrimidines / Q000009:adverse effects*; D012074:Remission Induction; D012512:Sarcoma, Ewing / Q000556:secondary / Q000628:therapy; D013737:Testis / Q000473:pathology; D019772:Topotecan / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D010879:Piperazines; D011743:Pyrimidines; D005047:Etoposide; D000077146:Irinotecan; D019772:Topotecan; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D002166:Camptothecin